within Pharmacolibrary.Drugs.ATC.N;

model N05CA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 2.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05CA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Aprobarbital is a barbiturate derivative with sedative, hypnotic, and anticonvulsant properties. It was previously used for the treatment of insomnia and epilepsy, but is rarely used or approved today due to the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans based on class information for barbiturates, as no direct human PK data for aprobarbital is found in available literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05CA05;
